NICE expands access for nusinersen in spinal muscular atrophy (SMA)

Following a review of data collected as part of a managed access agreement, NICE have agreed that access to nusinersen should be allowed in type III SMA, as well as continued use >12 months in patients who had not regained the ability to walk.

Source:

PharmaTimes